This phase II MATCH screening and multi-sub-trial studies how well treatment that is directed by genetic testing works in patients with solid tumors, lymphomas, or multiple myelomas that may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanced) and does not respond to treatment (refractory). Patients must have progressed following at least one line of standard treatment or for which no agreed upon treatment approach exists. Genetic tests look at the unique genetic material (genes) of patients' tumor cells. Patients with genetic abnormalities (such as mutations, amplifications, or translocations) may benefit more from treatment which targets their tumor's particular genetic abnormality. Identifying these genetic abnormalities first may help doctors plan better treatment for patients with solid tumors, lymphomas, or multiple myeloma.
- Patients must be >= 18 years of age. Because no dosing or adverse event data are currently available on the use of study investigational agents in patients < 18 years of age, children are excluded from this study
|
-
Patients of childbearing potential must have a negative serum pregnancy test within 2 weeks prior to registration
|
- patients that are pregnant or breast feeding are excluded
|
- a patient of childbearing potential is anyone, regardless of sexual orientation or whether they have undergone tubal ligation, who meets the following criteria:
Has achieved menarche at some point
Has not undergone a hysterectomy or bilateral oophorectomy
|
- or
Has not been naturally postmenopausal for at least 24 consecutive months (i.e., has had menses at any time in the preceding 24 consecutive months)
|
-
Patients must not expect to conceive or father children by using accepted and effective method(s) of contraception or by abstaining from sexual intercourse prior to study entry, for the duration of study participation, and for 4 months after completion of study
|
- should a patient or partner of the patient become pregnant or suspect a pregnancy while participating in this study, the treating physician should be informed immediately
|
-
Patients must have measurable disease
|
-
Patients must have Eastern Cooperative Oncology Group (ECOG) performance status =< 1 and a life expectancy of at least 3 months
|
- Patient must not require the use of full dose coumarin-derivative anticoagulants such as warfarin
|
- low molecular weight heparin is permitted for prophylactic or therapeutic use
|
- factor X inhibitors are permitted
NOTE: Warfarin may not be started while enrolled in the EAY131 study
Stopping the anticoagulation for biopsy should be per site standard operating procedure (SOP)
|
-
Patients must not currently be receiving any other investigational agents
|
-
Patient must not have been assigned to step 1 treatment based on a "rare variant" determined by a designated outside laboratory
|